Zero Cholesterol Tomato Basil Soup
December 1, 2007 by Daddy
Filed under Recipe Submissions
Ingredients
3 #s ripe plum tomatoes cut in half (I buy them at Costco)
¼ them
2 t olive oil
1 ½ t pepper
2 cups chopped onion
6 cloves garlic
2T “I can’t believe its not butter”
¼ crushed red pepper flakes
28 oz canned Plum Tomato Sauce with their juice
4 cups basil packed
1 t. fresh thyme leaves
I quart chicken stock (used non fat – you can get at Trader Joe’s)
Non fat sour cream
Preparation:
Pre heat oven to 400. Toss tomatoes with olive oil, salt , pepper. Spread tomatoes in one layer on a baking sheet and roast for 45 min. In an 8 quart stockpot on medium high, sauté onions and garlic with 2 tablespoons of olive oil and no cholesterol butter, and red pepper flakes until onions start to brown. Add canned tomatoes, basil, thyme, and chicken stock. A dd roasted tomatoes, include liquid on the baking sheet. Bring to boil and simmer 40 min. Put into a food processor with a little non fat sour cream and process.
You can serve with a dollop of non fat sour cream
Scientific Research Papers For Niemann Pick Type C
December 1, 2007 by Daddy
Filed under Scientific Papers
The Complex Gene Scientists Are Studying Niemann Pick Type C1 – Chromosome 18q11-q12
UT Southwestern – Brown & Goldstein Lab
- Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport in Niemann-Pick type C cells
- Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol
- NPC2 facilitates bidirectional transfer of cholesterol between Niemann Pick Type C1 and lipid bilayers, a step in cholesterol egress from lysosomes
- Niemann Pick Type C1 and Niemann Pick Type C2 function as a tag team duo to mobilize cholesterol
- Purified NPC1 Protein: Binding of Cholesterol and Oxysterols (Large PDF)
- Purified NPC1 Protein: Localization of Sterol Binding (Large PDF)
UT Southwestern – Dr. John Dietschy Lab
- Cyclodextrin overcomes the transport defect in nearly every organ of the newborn or mature NPC1 mouse leading to excretion of the sequestered cholesterol as bile acid
- Reversal of defective lysosomal transport in Niemann Pick Type C disease ameliorates liver dysfunction and neurodegenerations in NPC mouse mouse
- GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice
- Treatments that affect lifespan of NPC1 Mouse
- Liver Cell Death
- Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease
- Cholesterol Accumulation and Liver Cell Death in Mice With Niemann-Pick Type C Disease
Einstein University – Dr. Steven Walkley Lab
- Chronic Cyclodextrin Treatment of NPC Disease Ameliorates Neuronal Choleseterol Storage and Glycosphingolipid Storage and Disease Progression
- Chronic Cyclodextrin Administration Amerloriates Clinical Symptoms and Storage Accumulations in Niemann Pick Type C
Washington University St. Louis: Dr. Daniel Ory Lab
- Oxysterol Patent Application for Niemann Pick Type C
- Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking
Melbourne Neuropsychiatry Center- Dr. Mark Walterfang Lab
- White and gray matter alterations in adults with Niemann Pick Type C disease
- Saccades in adult Niemann-Pick disease type C reflect frontal, brainstem, and biochemical deficits
- Size and Shape of the Corpus Callosum in Adult Niemann-Pick Type C Reflects State and Trait Illness Variables
Oxford University- Dr. Fran Platt Lab
Stanford University – Dr. Matt Scott Lab
- Link between Niemann Pick Type C and Alzheimer’s
- Clues to Neuro Degeneration in Niemann Pick Type C With Global Gene Expression Profiling
- A Drosophila model of the Niemann-Pick type C lysosome storage disease: dnpc1a is required for molting and sterol homeostasis
Mt. Sinai – Dr. Yiannis Ioannou Lab
Cornell University – Dr. Fred Maxwell Lab
- Screening to Revert Cholesterol Accumulation
- Sterol, Protein and Lipid Trafficking in Chinese Hamster Ovary Cells with NPC1 Defect
- Automated Microscopy Screening
University of Pennsylvania – Dr. Charles Vite Lab (researchers Niemann Pick Type C Cats)
- 2 Hydroxypropyl Cyclodextrin Raises Hearing Threshold in Normal Cats and in Cats With Niemann-Pick Type C Disease
- Clinical, Electrophysiological, and Serum Biochemical Measures of Progressive Neurological and Hepatic Dysfunction in Feline Niemann-Pick Type C Disease
University of Geneva: Greunberg Lab
Dr. Peter Penchev Papers
UCSF
University of Arizona
University of Alberta – Dr. Jean Vance Lab
- Lipid Homeostasis and Lipoprotein Secretion in Niemann-Pick C1-deficient Hepatocytes
- NPC1 Protein Recycling Endosomes of Presynaptic Nerve Terminals
Mayo Clinic – Dr. Marc C. Patterson Papers
- Consequences of NPC1 and NPC2 loss of function in mammalian neurons
- MIGLUSTAT IN NIEMANN-PICK TYPE C (NPC) DISEASE: A 1-YEAR INTERIM ANALYSIS
- The pathophysiology and mechanisms of Niemann Pick Type C disease
- Niemann Pick Type C overview paper – Marc Patterson
- Current Understanding and Treatment Options For Niemann Pick Type C
Imaging Papers
- Clinical experience with miglustat therapy in pediatric patients with Niemann–Pick disease type C – a case series
- Diffusion tensor Imaging in Niemann Pick Type C disease
General NPC Papers
- The adult form of Niemann–Pick disease type C
- The natural history of Niemann–Pick disease type C in the UK
- The National Niemann–Pick C1 Disease Database: Report of Clinical Features and Health Problems
- New Lysosomal Storage Disorders (LSDs) Unfolding
- Childhood, Teen and Young Adult Dementias
- Niemann-Pick type C disease (NP-C) is a considerable diagnosis in juvenile and adult-onset psychiatric disorders
Alzheimer’s Papers
- HO-1 and Neurodegeneration Oxysterols
- Brain Sterol dysregulation in Alzheimers
- Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin
Other NPC Papers of Significance:
- Identification of Novel Genes and Pathways Regulating SREBP Transcriptional Activity
- Mechanism of Cholesterol Transfer
- Demonstration of lysosomal localization for the mammalian ependymin-related protein
- Non Vesciular Sterol Tranport: two protein families and a sterol sensor
- Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders
- Endosomal Accumulation of Toll-Like Receptor 4 Causes Constitutive Secretion of Cytokines and Activation of Signal Transducers and Activators of Transcription in Niemann–Pick Disease Type C (NPC) Fibroblasts: A Potential Basis for Glial Cell Activation in the NPC Brain
- The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways
- Mechanism of cholesterol transfer from the Niemann-Pick Type C2 protein to model membranes supports a role in lysosomal cholesterol transport
- Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1
Niemann Pick Type C gene and relationship to viruses (HIV, Ebola, RSV, etc)
Cyclodextrin Papers
- Cyclodextrin does not cross the Blood Brain Barrier – Final Cyclodex Poster Kings College London
- 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD) A toxicology review
- Cyclodextrin in Rats and Dogs
- Cyclodextrins in products
- 7 Ketocholeterol and Cyclodextrin
- Sporonox IV Drug From Janssen Pharma contains Cyclodextrin
- Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages
- Safety of Parenteral Hydroxypropyl Beta Cyclodextrin
- Cyclodextrins enhance drug delivery
- Cyclodextrins promote protein aggregation posing risks
- ADRENOLEUKODYSTROPHY Cyclodextrin Paper
- Lajos Cyclo Ideas
The National Chemical Genomics Center, Rockville, Maryland
We are leaving tomorrow, Nov. 26, 2008, for a special meeting to discuss accelerating research into Niemann Pick Type C disease at the National Chemical Genomics Center (NCGC) located in Rockville, Maryland.
The National Institutes of Health (NIH) established the NCGC to create a national resource for the study of protein and cell functions so they can learn more about the biology of diseases and genetics.
We are going to get a tour of the state-of-the-art high throughput screening robotic operation and we can’t wait to learn more. The NCGC is one component of the NIH’s Roadmap Initiatives, an innovate project to create research centers, teams and technologies to accelerate new discoveries in biomedical research.
You can read more about the entire NIH project here.
Moonlight Garden Gala Invite
November 18, 2007 by Daddy
Filed under Gala Invite
The Addi and Cassi Fund Presents:
Moonlight Garden Gala
A benefit for Childhood Alzheimer’s (NP-C)
On Saturday, May 10, 2008, 1000 friends and family joined us for a sold out star-filled night at the new Downtown Reno Ballroom to help find a cure to “Childhood Alzheimer’s” (Niemann-Pick Type C), a rare, progressive and fatal neurological disease that is robbing children of all ages around the world of their ability to walk, talk, or even remember the name of their favorite stuffed animal.
The event was a mystical evening of hope, wonder and childhood dreams as we honored our four-year-old twins, Addi and Cassi Hempel, and children all over the world who suffer from Niemann Pick Tyep C. Our guests will be treated to an elegant evening with a celebrity performance by Meilnda Doolittle and Terry Fator. We held silent and live auctions, uplifting music in this enchanting atmosphere and transformed the ballroom into a beautiful moonlit garden, designed in the spirit of a child’s imagination, with tree-lined paths, twinkle lights, fireflies and a fountain of wishes.
Alzheimers Touches Kids
November 18, 2007 by Daddy
Filed under NPC Family Stories
USA TODAY, May 2006 By Kathleen Fackelmann
Jessica Leoni has a disease that resembles Alzheimer’s.
But she’s nowhere near 65, the age at which the risk of dementia starts to zoom.
She’s just 8 years old. Up until last year she led a typical kid’s life, complete with ballet recitals, birthday parties and lots of friends. On Memorial Day weekend, that life came to a crashing halt as Jessie suffered the first of many seizures that would rack her small body.
"Our life changed overnight," says Jessica’s mother, Lisa.
Lisa and her husband, Anthony Leoni, had never heard of Niemann-Pick Type C, or NPC, before Jessica, or Jessie, was diagnosed with the disease. They now know that kids with NPC lose their ability to walk, talk or even to remember the name of a favorite stuffed animal.
And they know the incurable disease, which afflicts about 500 children in the USA, has been called the pediatric version of Alzheimer’s, a disease that afflicts 4.5 million people — most of them seniors — in the nation today.
Researchers, many of them financed by the Ara Parseghian Medical Research Foundation, are racing to find treatments that would help kids such as Jessie. "The goal of the Foundation is to find a cure," says Cindy Parseghian, the daughter-in-law of legendary Notre Dame football coach Ara Parseghian.
Cindy, along with her husband and father-in-law, started the foundation in 1994 after three of her four children had been diagnosed with NPC. Today all three of the Parseghian children with NPC have died, yet Cindy continues her fight, a fight that might also help people with Alzheimer’s.
Alzheimer’s is thought to be caused by abnormal brain deposits, almost identical to the deposits seen in children with NPC, says NPC researcher Steven Walkley of the Albert Einstein College of Medicine in the Bronx. Children who live long enough with NPC also can develop dementia, he says.
"A lot of us think that if we could really understand NPC, maybe it would help us understand Alzheimer’s," he says.
For the Leoni family, however, the daily reality comes down to a fight to keep their only daughter alive.
A race against time
"She’s down to three to five seizures a day," Lisa Leoni says. That’s an improvement. Since last May, Jessie has been hospitalized four times and sometimes she has had as many as 25 seizures in a single day.
But on this rainy day in Los Angeles, Jessie is getting physical therapy, which won’t stop the seizures or even slow the underlying disease. The goal of physical therapy is simply to rebuild muscle strength and flexibility.
She’s in a room decorated with stuffed animals, Minnie Mouse and the memorabilia of a life that up until a year ago included ballet and tap dance lessons.
Jessie still hasn’t developed dementia, but the disease already has damaged her brain and robbed her of abilities that most children take for granted. Jessie can’t stand on her own anymore, so the physical therapist gently supports her as she stands up and grins —looking every bit the budding ballerina she was a year ago.
"She’s a ham," Lisa Leoni says. Leoni hopes the physical therapy will hold the line on Jessie’s decline until doctors find the right combination of drugs that will ease the seizures for good.
But the Leoni family faces a race against time. Even if doctors stop the seizures, no one really knows how much damage the underlying disease has done.
"Our hope is that the disease isn’t progressing in ways that we can’t see," Anthony Leoni says.
The disease is a progressive disorder of cholesterol metabolism, says Marc Patterson, a pediatric neurologist at Columbia University in New York. A genetic flaw causes fatty substances such as cholesterol to build up in cells, including brain cells. As cells get clogged with fat, damage occurs, which leads to symptoms of the disease, such as difficulty walking and talking, and sometimes seizures.
"There is no effective therapy at the moment," Patterson says.
NPC is caused by a mutation in a gene on chromosome 18. Children with the disease have inherited two copies of the abnormal gene. They often appear healthy at birth and only later start to develop serious symptoms.
Faith and fear
At the Leoni family home, Jessie is walking slowly across the living room, which is bathed in muted light. A framed photo on the wall behind her shows Jessie as a cherub of a baby with the dark, curly hair of her Italian-Irish ancestry.
Jessie’s parents had no idea of the ordeal that stretched before them when she was born.
The first sign of something amiss was just a slightly enlarged liver when Jessie was just 2 months old. Then, in December 1997, Jessica was hospitalized for tests. More tests, including a genetic test for NPC, followed.
The Leoni couple had their first Christmas at home with their baby daughter. Just a few months later, in April 1998, they got the news that would change their life.
As the news sunk in, Lisa Leoni remembers numbness first, followed by fear. Then, for days after that, she turned to the only thing she knew that would sustain her.
"I just kept praying to God: ‘Don’t take my baby away.’ "
What followed was a period during which Jessica looked normal but developed slowly. She walked and talked and went to kindergarten. But for the Leonis, the joy that came with those milestones was tinged with the knowledge that at any moment the disease might really kick in.
"Sometimes I wondered why we needed to know," Lisa Leoni says now. "We lived in fear."
That fear was grounded in reality: Jessie had to repeat first grade because she had fallen behind in her schoolwork. And by December 2004, Jessie had started to falter in ballet class.
"Her last recital I could tell the difference," Lisa Leoni says. "She knew every step, but her timing was off."
Living for the moment
In April 2005, Jessica made her first communion, and a photo of that event appears to show a healthy 7-year-old with a toothy grin. Her father’s hand rests protectively on Jessica’s shoulder.
But the disease was silently damaging her brain and other organs. A month later, the disease exploded in the form of a grand mal seizure. That day Jessie crossed the line from a relatively normal childhood to a life marked by a progressive illness.
Almost a year has gone by:
• Jessie can no longer walk without help.
• She must be fed baby formula through a tube.
• Instead of going off to school this past fall, Jessica stayed behind — mostly living her life on the couch. A poster of her classmates, now in the second grade, hangs on the wall nearby.
Jessie, who can no longer talk, communicates by blinking her eyes and smiling. But Lisa Leoni knows the disease eventually will take away her daughter’s ability to understand. "The idea that she will lose her mind — that is unbearable to me," she says.
The couple still holds out hope that medical advances will buy their daughter more time. They know that a drug, Zavesca — used to treat Gaucher’s disease, a rare, genetic disorder — has been shown to significantly delay NPC in mice.
Recently Marc Patterson’s team tested the drug, which is made by Actelion Pharmaceuticals, in a small number of people, including children with the disease. The drug appeared to slow the disease, Patterson says, adding that even a delay would be a big deal for such children.
Still, Jessie’s parents know that Zavesca might not pan out. "You start to get hopeful, but then you realize how slow the research is," Lisa Leoni says.
So for today she’s not banking on a drug that might or might not materialize. She settles for everyday moments with her daughter: The smile that lights up Jessie’s face as she walks slowly across the room. The giggle that erupts when her father gently pokes her bellybutton. The joy that Jessie got out of a recent visit to her school.
"We are incredibly blessed," Lisa Leoni says. "I just keep telling Jessie that we’re just going to have to find new ways of living."








